Twist Bioscience (TWST)
(Delayed Data from NSDQ)
$53.90 USD
+0.34 (0.64%)
Updated Jul 19, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
TWST 53.90 +0.34(0.64%)
Will TWST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TWST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TWST
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
TWST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
Other News for TWST
Twist Bioscience Announces Clinical Progression of Pure Biologics’ Antibody Candidate Discovered Using Twist’s Antibody Libraries
Twist Bioscience says first patient dosed in Pure Biologics' BA-0405 study
Buy Rating Justified by Strong Demand and Strategic Expansion of Twist Bioscience’s Express Genes
Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies